These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 17933034

  • 1. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
    Quintás-Cardama A, Kantarjian H, Cortes J.
    N Engl J Med; 2007 Oct 11; 357(15):1557; author reply 1557-8. PubMed ID: 17933034
    [No Abstract] [Full Text] [Related]

  • 2. Chronic myelogenous leukemia progenitors display a genetically unstable personality.
    Rodrigues MS, Sattler M.
    J Natl Cancer Inst; 2007 May 02; 99(9):662-3. PubMed ID: 17470729
    [No Abstract] [Full Text] [Related]

  • 3. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.
    J Coll Physicians Surg Pak; 2008 Mar 02; 18(3):176-8. PubMed ID: 18460249
    [Abstract] [Full Text] [Related]

  • 4. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P, Dilea C, Yin OQ, Woodman RC, Mestan J, Manley PW.
    J Clin Oncol; 2010 Apr 10; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract] [Full Text] [Related]

  • 5. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L, Volzone F, Riva G, Soverini S, Martinelli S, Iacobucci I, Gnani A, Barozzi P, Forghieri F, Morselli M, Zanetti E, Maccaferri M, Baccarani M, Martinelli G, Torelli G, Luppi M.
    Br J Haematol; 2009 Jul 10; 146(2):227-30. PubMed ID: 19545285
    [No Abstract] [Full Text] [Related]

  • 6. Imatinib and regression of type 2 diabetes.
    Veneri D, Franchini M, Bonora E.
    N Engl J Med; 2005 Mar 10; 352(10):1049-50. PubMed ID: 15758023
    [No Abstract] [Full Text] [Related]

  • 7. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Hwang YY, Tse E, So JC, Wan TS, Kwong YL.
    Am J Hematol; 2009 May 10; 84(5):302-5. PubMed ID: 19338042
    [No Abstract] [Full Text] [Related]

  • 8. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
    Ou J, Vergilio JA, Bagg A.
    Am J Hematol; 2008 Apr 10; 83(4):296-302. PubMed ID: 17957805
    [Abstract] [Full Text] [Related]

  • 9. CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
    Goldman J.
    Lab Hematol; 2004 Apr 10; 10(3):181-4. PubMed ID: 15529444
    [No Abstract] [Full Text] [Related]

  • 10. Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
    Arancibia AM, Bendit I, Epelman S.
    Pediatr Blood Cancer; 2008 May 10; 50(5):1078. PubMed ID: 18085674
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
    Druker BJ.
    Oncogene; 2002 Dec 09; 21(56):8541-6. PubMed ID: 12476300
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A.
    Nepal Med Coll J; 2007 Dec 09; 9(4):292. PubMed ID: 18298026
    [No Abstract] [Full Text] [Related]

  • 15. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB.
    J Assoc Physicians India; 2007 Feb 09; 55():99-100. PubMed ID: 17571737
    [No Abstract] [Full Text] [Related]

  • 16. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM, Melo JV.
    Acta Haematol; 2008 Feb 09; 119(4):212-7. PubMed ID: 18566539
    [Abstract] [Full Text] [Related]

  • 17. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
    Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC.
    Leuk Res; 2008 Sep 09; 32(9):1476-9. PubMed ID: 18308388
    [Abstract] [Full Text] [Related]

  • 18. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
    Jiménez-Velasco A, Barrios M, Alcalá M, Heiniger AI.
    J Clin Oncol; 2010 Jun 20; 28(18):e310; author reply e311. PubMed ID: 20479423
    [No Abstract] [Full Text] [Related]

  • 19. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
    Nardi V, Raz T, Cao X, Wu CJ, Stone RM, Cortes J, Deininger MW, Church G, Zhu J, Daley GQ.
    Oncogene; 2008 Jan 31; 27(6):775-82. PubMed ID: 17684485
    [Abstract] [Full Text] [Related]

  • 20. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
    Miglino M, Varaldo R, Colombo N, Grasso R, Clavio M, Garuti A, Aquino S, Albarello A, Sessarego M, Gobbi M.
    J Exp Clin Cancer Res; 2006 Sep 31; 25(3):321-4. PubMed ID: 17167971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.